MZF1 and breast carcinoma: As MZF1 was associated with better survival in breast cancer patients, and because MZF1 expression decreased upon treatment with BET inhibitors, Kanojia et al. (2020) performed knockdown/overexpression studies and ChIP-qPCR, confirming that MZF1 could bind to the TUBB3 loci and repress TUBB3/βIII-tubulin expression.